ASCO 2022 Updates in HR+/HER2- eBC

 

ASCO 2022 Updates in HR+/HER2- eBC
11:15

UNC Lineberger Comprehensive Cancer Center

Identifying High-Risk Patients to Guide Management in HR+/HER2- Early Breast Cancer

FEATURING Yara Abdou
  • 178 views
  • July 18, 2022
  • 1
08:45

Nadia Harbeck

Adjuvant Abemaciclib Combined With ET in HR+, HER2- High-Risk EBC: Updated Results From MonarchE

  • 2,110 views
  • October 26, 2021
  • 19
07:17

ASCO 2022 Conference Coverage

ASCO 2022 Adjuvant Abemaciclib for High-Risk Early Breast Cancer: Factors Increasing the Rate of Treatment Discontinuations in monarchE

FEATURING Sara Tolaney
  • 383 views
  • July 26, 2022
  • 1
54

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Adjuvant Abemaciclib for High-risk Early Breast Cancer: Factors Increasing the Rate of Treatment Discontinuations in monarchE

FEATURING Sara Tolaney
  • 29 views
  • July 26, 2022
08:04

ASCO 2022 Conference Coverage

ASCO 2022 on OPTIMA Preliminary Trial: Disparity Between Ki67 Measurements and Tumor Gene Expression Tests in Hormone-Sensitive EBC

FEATURING Robert Stein
  • 1,406 views
  • June 7, 2022
  • 2
05:15

Cedars Sinai

ASCO 2022: Identification of Transcriptional Changes With MammaPrint and BluePrint in EBC After Neoadjuvant Chemo

FEATURING Alice Chung
  • 203 views
  • June 7, 2022
  • 1
10:19

ASCO 2022 Conference Coverage

ASCO 2022 on Estradiol Levels in Premenopausal Women With HR+ BC on Ovarian Function Suppression With GnRH Agonists

FEATURING Megan Tesch
  • 2,973 views
  • June 8, 2022
  • 5
32

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Estradiol Levels in Premenopausal Women With HR+ BC on Ovarian Function Suppression With GnRH Agonists

FEATURING Megan Tesch
  • 31 views
  • June 8, 2022
31:43

Total Health

2022 MDONS Conference Breast Cancer Updates

FEATURING Fengting Yan
  • 146 views
  • June 7, 2022
  • 1
13:32

ASCO 2022 Conference Coverage

ASCO 2022 on ABCSG-18 Trial: Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer: Fracture Reduction & Survival Results

FEATURING Michael Gnant
  • 1,003 views
  • June 9, 2022
  • 5
05:13

ASCO 2022 Conference Coverage

ASCO 2022 Optimization of the Duration of Adjuvant Endocrine Therapy in Early Breast Cancer

FEATURING Barbara Pistilli
  • 28 views
  • June 13, 2022
28

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Optimization of the Duration of Adjuvant Endocrine Therapy in Early Breast Cancer

FEATURING Barbara Pistilli
  • 19 views
  • June 13, 2022
05:00

ecancer

ASCO 2022 on the Adjuvant Endocrine Therapy for ER+/HER2- Breast Cancer

FEATURING Etienne Brain
  • 113 views
  • June 23, 2022
22:29

ESMO 2022 Conference Coverage

ESMO 2022 on Adjuvant Endocrine Therapy for BC: Who Needs More Than 5 Years, Which Regimen, and What Duration Beyond 5 Years?

FEATURING Evandro de Azambuja
  • 2,472 views
  • September 15, 2022
  • 12